Wave Life Sciences Ltd.
WVE$489M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaSINGAPORE287 employees
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Jun 27, 2026
15wMarket Overview
Stock performance and key metrics
WVE News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
WVE-006
Alpha-1 Antitrypsin Deficiency
WVE-N531
Duchenne Muscular Dystrophy
SAD: 30mg WVE-003
Huntington Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
WVE-006 | Phase 2 | Alpha-1 Antitrypsin Deficiency | - | - |
WVE-N531 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
SAD: 30mg WVE-003 | Phase 2 | Huntington Disease | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply